Aprea Therapeutics Reports Promising Early Clinical Data for DNA Damage Response Inhibitors
核心洞察
Aprea Therapeutics' WEE1 inhibitor APR-1051 demonstrated disease stabilization in 3 out of 4 patients at 100 mg once daily in heavily pretreated gastrointestinal and gynecologic cancers.
The company identified a recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, its first-in-class macrocyclic ATR inhibitor targeting DNA damage response pathways.
Both clinical programs are advancing with manageable safety profiles, focusing on biomarker-defined patient populations with high unmet medical needs.
Aprea Therapeutics reported encouraging early clinical results for its DNA damage response (DDR) inhibitor programs, with both lead compounds showing signs of anti-tumor activity in heavily pretreated cancer patients. The clinical-stage biopharmaceutical company announced third quarter 2025 financial results alongside clinical updates for APR-1051, a WEE1 kinase (搜索) inhibitor, and ATRN-119, an ATR kinase (搜索) inhibitor.
WEE1 Inhibitor Shows Disease Stabilization
In the ongoing Phase 1 ACESOT-1051 dose-escalation trial, APR-1051 demonstrated clinical activity at the 100 mg once daily dose level. Three out of four patients achieved stable disease per RECIST v1.1 criteria in heavily pretreated gastrointestinal and gynecologic malignancies (搜索). Disease stabilization was observed in patients with FBXW7 (搜索), CCNE1 (搜索), and KRASG12V (搜索) + TP53 (搜索) alterations, molecular profiles known to drive replication stress and WEE1 dependency.
"For APR-1051, our WEE1 kinase (搜索) inhibitor, we're encouraged by early signs of anti-tumor activity to date in the ongoing ACESOT-1051 trial, including 3 out of 4 patients with stable disease in the 100 mg once daily cohort," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea.
Following successful clearance of the 100 mg cohort, dose escalation has progressed to Dose Level 7 (150 mg once daily) with the goal of identifying doses that maximize therapeutic benefit while maintaining an acceptable safety profile. APR-1051 was manageable with mostly Grade 1 or 2 adverse events, which were mainly gastrointestinal events and fatigue.
APR-1051 is designed as a potent and selective small molecule WEE1 inhibitor to potentially solve tolerability challenges of the WEE1 class. The compound is being advanced as a monotherapy in biomarker-defined cancers likely to respond to WEE1 inhibition, with cancers over-expressing Cyclin E (搜索) representing a high unmet medical need where patients have poor prognosis and currently lack effective therapy options.
ATR Inhibitor Reaches Recommended Phase 2 Dose
ATRN-119, described as a potent and highly selective first-in-class macrocyclic ATR inhibitor, has reached a significant milestone with the identification of its recommended Phase 2 dose (RP2D) of 1,100 mg once daily. The compound is being evaluated in the open-label Phase 1/2a clinical trial ABOYA-119 as monotherapy in patients with advanced solid tumors (搜索) having at least one mutation in a defined panel of DDR-related genes.
As of September 8, 2025, 43 patients with advanced solid tumors (搜索) have been enrolled in the ABOYA-119 trial. ATRN-119 is designed for use in patients with tumors harboring mutations in DDR-related genes, representing a high unmet medical need where patients often have poor prognosis and currently lack effective therapeutic options.
Strategic Pivot to Combination Approaches
Following RP2D determination, Aprea is strategically pausing further enrollment in both once daily and twice daily monotherapy dosing arms of the ABOYA-119 trial to consider combination studies aimed at maximizing therapeutic benefits. The company is currently in discussions with leading academic centers to explore combining ATRN-119 with radiation in patients with HPV+ head and neck cancer (搜索), an indication where synergistic anti-tumor effects have been observed in preclinical data.
Additional investigator-led studies evaluating ATRN-119 in combination with immunotherapy agents and antibody-drug conjugates are also being explored. For APR-1051, future studies may evaluate the compound in combination with checkpoint inhibitors to address unmet medical needs across distinct patient populations.
Conference Presentations and Financial Position
Both programs were featured in poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025. The presentations summarized preliminary results with data cutoff dates of September 17, 2025 for APR-1051 and September 8, 2025 for ATRN-119.
Financially, Aprea reported cash and cash equivalents of $13.7 million as of September 30, 2025, compared to $22.8 million as of December 31, 2024. The company believes its current cash position will be sufficient to meet projected operating expenses and capital expenditure requirements into the fourth quarter of 2026. The company reported an operating loss of $3.1 million for the third quarter of 2025, compared to an operating loss of $4.1 million in the third quarter of 2024.